LakeShore Biopharma Co., Ltd

LSBNASDAQHealthcare

$0.63

+$0.00(+0.00%)

Market Cap$25840359

P/E Ratio—

52W High$8.6

52W Low$0.574

Avg Volume348K

Open$0.79

Beta0.57

SEC Filings

Foreign Private Issuer · Files 20-F / 6-K

LakeShore Biopharma Co., Ltd (LSB) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001946399 · LSB · NASDAQ · as of Jun 9, 2026

Filing snapshot

149

Total Filings

6-K

Latest Form

2026-05-28

Most Recent

2021

Filing Since

Financials Earnings View All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001946399 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY

Filed Date

2025-07-31

Fiscal Year End

Jul 31, 2025

Accession No.

0001213900-25-069880

Primary Document

ea0248839-20f_lakeshore.htm

View on SEC EDGAR Download PDF Filing Index

Source: data.sec.gov · CIK 0001946399 · Accession 0001213900-25-069880

Latest Key Filings

6-KQuarterly Report

REPORT OF FOREIGN PRIVATE ISSUER

2026-05-28

View 6-K on SEC

8-KCurrent Report

No recent filings

Form 4Insider Activity

Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144

Filed Date

Form Type

Description

View

2026-05-28

6-K

Current Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

0001213900-26-061817

View

6-KCurrent Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

2026-05-28

View

2026-05-28

SC 13E3/A

AMENDMENT NO. 7 TO SCHEDULE 13E-3

0001213900-26-061798

View

SC 13E3/ASC 13E3/A

AMENDMENT NO. 7 TO SCHEDULE 13E-3

2026-05-28

View

2026-05-08

SC 13E3/A

AMENDMENT NO. 6 TO SCHEDULE 13E-3

0001213900-26-053596

View

SC 13E3/ASC 13E3/A

AMENDMENT NO. 6 TO SCHEDULE 13E-3

2026-05-08

View

2026-04-29

SCHEDULE 13D/A

0001213900-26-048876

View

SCHEDULE 13D/ASCHEDULE 13D/A

SCHEDULE 13D/A

2026-04-29

View

2026-04-29

6-K

Current Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

0001213900-26-048850

View

6-KCurrent Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

2026-04-29

View

2026-04-10

Initial Statement of Beneficial Ownership

0001213900-26-042186

View

3Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

2026-04-10

View

2026-04-10

Initial Statement of Beneficial Ownership

0001213900-26-042181

View

3Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

2026-04-10

View

2026-04-01

Initial Statement of Beneficial Ownership

OWNERSHIP DOCUMENT

0001213900-26-038112

View

3Initial Statement of Beneficial Ownership

OWNERSHIP DOCUMENT

2026-04-01

View

2026-04-01

Initial Statement of Beneficial Ownership

OWNERSHIP DOCUMENT

0001213900-26-038111

View

3Initial Statement of Beneficial Ownership

OWNERSHIP DOCUMENT

2026-04-01

View

2026-04-01

Initial Statement of Beneficial Ownership

OWNERSHIP DOCUMENT

0001213900-26-038110

View

3Initial Statement of Beneficial Ownership

OWNERSHIP DOCUMENT

2026-04-01

View

2026-04-01

Initial Statement of Beneficial Ownership

OWNERSHIP DOCUMENT

0001213900-26-038108

View

3Initial Statement of Beneficial Ownership

OWNERSHIP DOCUMENT

2026-04-01

View

2026-04-01

SC 13E3/A

AMENDMENT NO. 5 TO SCHEDULE 13E-3

0001213900-26-038038

View

SC 13E3/ASC 13E3/A

AMENDMENT NO. 5 TO SCHEDULE 13E-3

2026-04-01

View

2026-03-31

Initial Statement of Beneficial Ownership

0001213900-26-036799

View

3Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

2026-03-31

View

2026-03-25

6-K

Current Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

0001213900-26-033849

View

6-KCurrent Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

2026-03-25

View

2026-03-25

SCHEDULE 13D/A

0001213900-26-033839

View

SCHEDULE 13D/ASCHEDULE 13D/A

SCHEDULE 13D/A

2026-03-25

View

Showing 1–15 of 149 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov) | Updated: Hourly | CIK: 0001946399 | Exchange: NASDAQ · Healthcare

LakeShore Biopharma Co., Ltd (NASDAQ: LSB) has submitted 149 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001946399, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is LakeShore Biopharma Co., Ltd's most comprehensive regulatory disclosure. The most recent LakeShore Biopharma Co., Ltd 10-K was filed on 2025-07-31 for fiscal year ending 2025. Historical LSB 10-K annual reports are available from 2022 through 2025.

Investors researching LakeShore Biopharma Co., Ltd SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Related Companies SEC Filings — Healthcare

ALLK SEC Filings →FRLN SEC Filings →LMNL SEC Filings →ANPC SEC Filings →GMTX SEC Filings →IVC SEC Filings →ELEV SEC Filings →SER SEC Filings →

→ LSB Financials → LSB Earnings → LSB Insider Trades

Frequently Asked Questions

LSB SEC Filings · 8 questions

LakeShore Biopharma Co., Ltd (LSB) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 149 filings and access original documents at no cost. LakeShore Biopharma Co., Ltd's CIK is 0001946399.

LSB SEC filingsLakeShore Biopharma Co., Ltd SEC documentsfind LSB 10-K